Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation

Study of QUAIL-100 in Patients With High Risk Acute Leukemia and Myelodysplastic Syndrome Who Have Received Hematopoietic Stem Cell Transplant

Trial Details

NCT ID
NCT07573111
Phase
PHASE1
Sponsor
Laguna Biotherapeutics, Inc.
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • QUAIL-100
Locations (sample)
  • Palo Alto, California, United States|37.44188,-122.14302

Key Eligibility Criteria

  • Weight \>/= 10 kg
  • Have received HLA-partially matched related or unrelated donor ab-depleted hematopoietic stem cell transplant (HSCT) for high-risk malignant diseas…
  • Lanksy/Karnofsky score \> 60
  • Participants of childbearing potential must agree to use contraception to prevent pregnancy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →